Advancing Tomorrow’s Cancer Medicines: Jacob Van Naarden Talks with Ken Herrmann and Johannes Czernin About Corporate Approaches to New Therapeutics Development

By sjmartinez • January 24, 2025

Van Naarden JS, Herrmann K, Czernin J. Advancing Tomorrow's Cancer Medicines: Jacob Van Naarden Talks with Ken Herrmann and Johannes Czernin About Corporate Approaches to New Therapeutics Development. J Nucl Med. 2025 Jan 23:jnumed.124.269354. doi: 10.2967/jnumed.124.269354. Epub ahead of print. PMID: 39848767.

Tags: Cardiology/Epi, Publications

Mid- to Late-Life Traditional Cardiovascular Risk Factor Exposure and Zero Coronary Artery Calcium: The ARIC (Atherosclerosis Risk in Communities) Study

Wang FM, Ballew SH, Folsom AR, Wagenknecht LE, Howard CM, Coresh J, Budoff MJ, Blaha MJ, Matsushita K. Mid- to Late-Life Traditional Cardiovascular Risk Factor[...]

South Asians and cardiometabolic health: A framework for comprehensive care for the individual, community, and population – An American society for preventive cardiology clinical practice statement

Rohatgi A, Anand SS, Gadgil M, Gujral UP, Jain SS, Javed Z, Jha M, Joshi PH, Manubolu VS, Nasir K, Natarajan P, Pagidipati N, Palaniappan[...]

Treated HIV infection is not associated with carotid vascular inflammation or plaque progression as assessed by dynamic contrast magnetic resonance imaging

Shakil S, Chen D, Isquith D, Sapp J, Pommier I, Chu B, Guo Y, Canton G, Balu N, Yuan C, Hatsukami T, Maynard C, Zhao[...]